Renata Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Renata Limited with three other
pharmaceutical manufacturers in Asia:
Yungshin Global Holding Corp
sales of 8.08 billion Taiwanese Dollars [US$290.40 million]
of which 68%
was Taiwan District),
Nippon Chemiphar Co., Ltd.
(31.76 billion Japanese Yen [US$290.25 million]
of which 96%
was Pharmaceutical Business), and
JiangSu WuZhong Pharmaceutical Development Co Ltd
based in CHINA
(1.87 billion Chinese Renmimbi [US$289.48 million]
of which 72%
During the third
quarter of 2021, sales at Renata Limited totalled
6.50 billion Bangladeshi Taka.
practically unchanged from the previous year, and is only
an increase of 0.4%
from the 6.48 billion Bangladeshi Taka in sales at the company during the third quarter of 2020.
During the first three quarters of 2021, sales totalled 21.04 billion Bangladeshi Taka, which is
than through the first three
quarters of 2020.
There appears to be at least some degree of seasonality in the sales at Renata Limited: during 5 of the previous 6
years, sales were highest during the fourth quarter.
The exception to this was during 2020, when the
third quarter was the best quarter, accounting for
26% of sales (during that same year, the
fourth quarter accounted for 23% of sales).
Renata Limited reported sales of 24.67 billion Bangladeshi Taka (US$290.18 million)
June of 2020.
increase of 8.2%
versus 2019, when the company's sales were 22.81 billion Bangladeshi Taka.
Sales at Renata Limited have increased during each of the previous five years
(and since 2015, sales have increased a total of 84%).